Small ubiquitin-like modifiers (SUMOs) are covalently conjugated to target proteins to regulate numerous biological processes, including subcellular localization, protein-protein interactions, and transactivational activities. While the majority of identified SUMO targets are cellular proteins, SUMO modified viral proteins have also been identified. In addition, there are a growing number of examples where viruses alter the sumoylation status of host cell proteins. Work from our laboratory has previously demonstrated that the human cytomegalovirus (HCMV) virion tegument protein pp71 binds to Daxx, a cellular transcriptional co-repressor, and promotes its sumoylation. Here we describe the in vivo techniques used to detect pp71-induced sumoylation of Daxx in a cotransfection system as well as the endogenous SUMO modified form of Daxx in HCMV-infected cells. The approaches we describe can be easily adapted to infections with other viruses and for the detection of sumoylation of other proteins.
Introduction
Since its discovery in 1996, the small ubiquitin-like (Ubl) modifier (SUMO), a $10 kDa protein, has received great attention because of its intriguing functions [1] [2] [3] [4] [5] . Sumoylation, a posttranslational modification, is a major regulator of protein function that plays an important role in a wide range of cellular processes, such as transcriptional regulation, DNA repair and chromatin remodeling (Reviewed in [6] ). In the fission yeast Schizosaccharomyces pombe, deletion of the SUMO/Pmt3 gene results in severe growth impairment [7] . In the budding yeast Saccharomyces cerevisiae, SUMO/Smt3 is essential for viability [8] , suggesting that SUMO is critical for the normal function of eukaryotic cells. The importance of sumoylation in mammals has also been confirmed through the knockout of Ubc9, a SUMO conjugating enzyme; transgenic mice lacking the gene for Ubc9 display embryonic lethality [9] . Hundreds of SUMO substrates have been previously described (Reviewed in [6] ), and several known targets among them are proteins of great interest (e.g., p53, PML, PCNA and IjBa), drawing further attention to this field. Although the biological consequences of SUMO modification are difficult to illustrate overall, when proteins are modified by SUMO, their functional properties, such as transcriptional activity, intracellular localization, stability, and protein-protein interactions, are usually modified [6] .
The biochemical mechanism of sumoylation, in contrast, is well understood (Reviewed in [10] ). Sumoylation is an enzymatic process that is biochemically analogous to, but functionally distinct from, ubiquitination. Similar to ubiquitination, sumoylation occurs in a multi-step reaction that covalently conjugates SUMO to a target protein by a single E1 activating enzyme (SAE1/2), a unique E2 conjugating enzyme (Ubc9), and an array of different E3 ligases. SUMO is most often conjugated to lysine residues in wKxE consensus sequences in target proteins, where w corresponds to hydrophobic amino acids, K is a lysine residue, x is any amino acid, and E is a glutamic acid residue. Sumoylation, however, can also occur at lysine residues outside of this motif, and not all wKxE motifs are sumoylated.
In mammalian cells, there are four SUMO isoforms, SUMO-1 to SUMO-4 [10] . Of these, SUMO-1, SUMO-2, and SUMO-3 are ubiquitously expressed, while SUMO-4 expression patterns remain to be determined, although there is one study illustrating SUMO-4 mRNA expression in the kidney [11] . Although some substrates have preferences for specific SUMO isoform modification, many substrates can be modified by different SUMO proteins. This is somewhat surprising because SUMO-2 and SUMO-3 only share 50% similarity with SUMO-1, while SUMO-2 and SUMO-3 share 95% identity with each other. SUMO-2/3 have the ability to form polySUMO chains in a similar manner to polyubiquitin chain formation, but SUMO-1 lacks this ability, and is often used as a polySUMO chain terminator [12] . Sumoylation can also occur at several lysine residues in a substrate (multisumoylation) [10] . In addition to covalent attachment of SUMO to target proteins, specific non-covalent SUMO interaction motifs (SIMs) have been identified [13, 14] . SIM-SUMO interactions have emerged as important mechanisms in the downstream effect of protein sumoylation.
For example, Daxx, a cellular transcriptional co-repressor, relies on its SIM to localize to PML nuclear bodies (PML-NBs) and to associate with sumoylated transcription factors to function in transcriptional regulation [15] .
Viruses have evolved strategies to manipulate and usurp the host sumoylation pathway (Reviewed in [16] ). Examples of viral proteins modified by SUMO as well as viral proteins that have effects on host sumoylation are constantly increasing. CELO adenoviral protein Gam1 targets the host E1 SUMO activating enzyme for proteasomal degradation, thereby inhibiting the host sumoylation system [17] . Kaposi's sarcoma associated herpesvirus encodes K-bZip, which acts as an E3 SUMO ligase to increase the sumoylation of p53 and Rb [18] . Human cytomegalovirus (HCMV) infection also affects host sumoylation. The viral IE1 protein disrupts PML-NBs through the modulation of sumoylation [19] , which is an important step for the virus in overcoming host antiviral responses. Work from our lab has also demonstrated that the HCMV pp71 protein enhances the sumoylation of Daxx, and this process requires its ability to interact with Daxx [20] .
The detection of sumoylated proteins in vivo can be challenging because only a small fraction of target proteins are sumoylated [6] . Sumoylation is a very dynamic process involving both SUMO conjugating enzymes and deconjugating enzymes (Reviewed in [21] ). Deconjugating enzymes, a family of isopeptidases known as SENPs (Sentrin-specific proteases) function in cleaving SUMO molecules from target proteins. This may explain the low level of detection for sumoylated proteins in vivo. Furthermore, some sumoylated proteins may not be isolated very well due to limited solubility or their tight interaction with organelles and structures of the cell. Because of these obstacles during the detection of sumoylation in vivo, many methods have been developed to investigate substrate sumoylation in vitro using the purified SUMO, SUMO conjugating enzymes, and substrates produced in bacteria [21, 22] . Although this is a powerful tool, the non-physiological conditions limit their biological relevance.
In this article, we describe protocols to detect protein sumoylation in virus-infected cells in vivo. We focus on techniques that have been used to detect in vivo HCMV pp71-mediated Daxx sumoylation as an example by describing: The protocol uses SDS as denaturant and it provides a reliable means to quickly generate protein extracts for Western blot analysis of covalent modification of Daxx. Maintaining denaturing conditions throughout the procedure has advantages in detecting ubiquitin or Ubl modifications. It not only improves protein solubilization, but also reduces false positives as non-covalent interactions are completely eliminated. To preserve native modifications by ubiquitin or Ubls, cysteine protease inhibitors such as N-ethylmaleimide (NEM) and iodoacetate (IAA) are often required. Lysis of cells in the presence of NEM alone or in combination with IAA has been shown to result in higher levels of conjugates compared to extract prepared without inhibitors (see Ref. [23] for example). In our experiment [20] , this treatment also resulted in the appearance of higher molecular weight conjugates of Daxx (Fig. 1) . Because the basic biochemical mechanisms of conjugation and deconjugation are common to ubiquitin and Ubls [6] , the method described here is widely applicable with little modifications to detect other protein Ub/Ubl modifications. The protocol is described for cultured cells grown in a single well of a 6-well plate, containing approximately 5 Â 10 5 cells. 
Detection of protein modifications
To detect a Ub/Ubl post-translational modification of the protein of interest, Western blot analysis can be used as protein modification by Ub/Ubl causes a molecular weight shift of about 10 kDa or larger on SDS-PAGE. Although this method would not indicate which modification occurs, Western blot analysis using total cell lysates is a good tool to readily examine if the test protein is modified and thus determine if further investigation of such modification is warranted. Table 1 Using this method [20] , we were able to detect the covalently modified form of Daxx induced by HCMV infection or by rAdpp71 transduction with an apparent molecular weight that was approximately 20 kDa larger than the unmodified form of Daxx ( Figs. 1 and 2) . We hypothesized that the pp71-induced Daxx modification may be sumoylation.
Cotransfection-coimmunoprecipitation assay to verify SUMO modification of Daxx
Because Daxx is found at PML-NBs where many proteins, including Daxx [27, 28] , are found to be covalently modified by SUMO, we asked if pp71 induced Daxx sumoylation. In this section, we describe a method to identify Daxx sumoylation by cotransfection-coimmunoprecipitation. Despite its potential limitation resulting from expression of exogenous gene products, cotransfection assays are widely used to investigate SUMO conjugation due to the following reasons: (a) epitope-tagging of transfected SUMO or the target protein makes it easy to immunoprecipitate the test protein, (b) enrichment of SUMO and/or the target protein allows the easy detection of target protein sumoylation, especially in cases where the endogenous sumoylated form is not abundant in cells, (c) expression levels of conjugating (i.e., SUMO E1 and E2) and/or deconjugating (i.e., SENP family proteins) enzymes are easily manipulated, (d) it is readily applicable for the identification of SUMO conjugation sites on target protein by mutating the potential SUMO acceptor lysine residues, and (e) SUMO paralog specificity (SUMO-1, SUMO-2, and SUMO-3) for target protein can be determined.
We have used this technique [20] for the identification of Daxx modification by pp71 (Fig. 3) . For transfection efficiency, we chose the human papillomavirus-negative cervical carcinoma cell line C33A instead of HCMV permissive cells. Other transfectable cell types, such as HeLa and 293, are applicable as well. The protocol here is described for cultured cells grown in a 10 cm dish, containing 6-7 Â 10 6 cells. NEM and IAA are included in all buffers for this method. blot analysis using appropriate antibodies as described in Section 2.2.
Troubleshooting:
Troubleshooting advice can be found in Table 1 Denaturing conditions for this experiment are often used to ensure that any detected SUMO proteins represent covalent modifications and not simply a non-covalent interaction through a SIM. Using this approach with FLAG antibodies for the IP and HA antibodies for Western blotting, our lab [20] was able to observe that co-expression of pp71 enhances the modified form of HA-Daxx by FLAG-SUMO-1 (Fig. 3, lanes 1 and 2) . Importantly, co-expression of the SUMO-specific protease SENP-1, which has ability to deconjugate all three SUMO paralogues from modified substrates [21] , prevents this modification of Daxx, validating that Daxx is specifically modified by SUMO (Fig. 3, lanes 3 and 4) . Mutant substrate that is predicted to not be sumoylated (e.g., mutant with lysine residues substituted by arginine) can also be used as a control to further confirm target protein sumoylation. Likewise, the same method can be applied to identify other Ubl modifications using plasmids expressing the desired Ubls in place of SUMO. Although this technique is powerful, the non-physiological condition (i.e., expression of exogenous gene products) is considered a limitation to this approach. Therefore, this single method alone cannot be regarded as solid proof of sumoylation.
Immunoprecipitation assay to detect endogenous sumoylated proteins
To complement cotransfection assays, a number of additional methods can be used to further investigate the sumoylation of a target protein, such as mass spectrometry (MS) analysis and IP of an endogenous protein. The mass spectrometric method generally involves affinity purification (e.g., Ni-NTA [30] ), proteolytic digestion, and analysis by MS. This approach is useful not only for identifying the proteins modified by SUMO, but also for mapping the residues that are covalently linked to SUMO. Although MS analysis is clearly powerful, there are drawbacks resulting from numerous false positives (nonspecific binding) and false negatives (loss of true SUMO conjugates). IP of the protein followed by Western blot analysis using endogenous proteins is one of the best approaches to detect true SUMO-modified substrates, although low abundance of the endogenous sumoylated target proteins often makes this approach challenging. In this section, we discuss the method used to detect endogenous Daxx sumoylation using the IP method (see Ref. [31, 32] for discussion of MS studies).
Two major technical challenges in this type of experiment are the relatively low levels of endogenous sumoylated protein and the quality of the antibody used to capture the sumoylated form of protein. In addition to specificity and affinity, the antibody used for IP should be clean with minimal background (high purity) because overexposure of the Western blot is often required to detect the low levels of modified protein species. IP of endogenous Daxx using the rabbit polyclonal Daxx antibody from Sigma Aldrich (Catalog number: D7810) seems to generate high background in our hands, though the Daxx antibody produces clean Western blots. Mouse monoclonal SUMO-1 antibody from Zymed Laboratories Inc. (Catalog number: 33-2400, now Invitrogen) specifically recognizes both the free form of SUMO-1 and the covalently attached SUMO-1 to target proteins with negligible background after IP followed by Western blotting. For this reason, we [20] chose the SUMO-1 antibody for the IP in order to detect endogenous SUMO modification of Daxx by pp71 (Fig. 4) .
Protein lysates from HFs infected with HCMV (or transduced with rAd-pp71) were analyzed by IP with a SUMO-1 antibody followed by Western blotting with a Daxx antibody. Lysates from mock-infected HFs were used as a control. When IP analysis was performed using 6 Â 10 6 cells in the SDS denaturing condition as described in Section 2.3, the level of IP was observed to be very low, making it hard to detect the sumoylated form of Daxx by Western blot analysis. To improve the IP condition, a modified IP protocol was employed. The major differences were as follows: (1 Using the modified protocol, we were able to detect endogenous sumoylated Daxx in HCMV-infected or rAd-pp71-infected cells. What makes the IP level different between the two methods, aside from the increased pre-IP input protein amounts, is not clear. It is possible that the different buffer compositions between SDS and RIPA IP buffers (i.e., differences in SDS or salt concentrations) cause altered affinity of the SUMO-1 antibody. Importantly, using RIPA buffer for the SUMO IP assay may result in the detection of non-covalent interactions in addition to covalent SUMO conjugations. For example, our IP-Western analysis [20] using RIPA buffer reveals a $120 kDa Daxx band corresponding to the unmodified Daxx in addition to a $140 kDa band corresponding to sumoylated Daxx (Fig. 4) . Coimmunoprecipitated unmodified Daxx is detected presumably from interactions with sumoylated proteins that bind to unmodified Daxx through its SIM. Nevertheless, this IP result implies that SUMO-1 can be conjugated to Daxx in physiological conditions, and that this conjugation is mainly detected after HCMV infection. Reciprocal IP/Western blot analysis can be also performed if good quality antibodies are available. The same protocol performed with different antibodies (e.g., anti-SUMO-2) will be applicable in determining which SUMO paralogue preferentially modifies Daxx in HCMV-infected cells.
Future directions
Proteomic approaches to identify and map sites of protein modification are becoming more reliable and more common. However, they still must be confirmed by widely accepted protocols such as the ones we present here. The major limitations of these approaches are the lack of quality antibodies, the need for ectopic protein overexpression, and the residual activity of isopeptidase (even in the presence of NEM and IAA) in crude cell lysates. Technologic improvement in these areas will increase the feasibility of these assays. The real future will not be simply in identifying sites of protein modification, but in determining their effects on protein function. This will be especially challenging for protein modifications like Daxx sumoylation, where only a vanishingly small fraction of the total protein is modified.
